DE69803750T2 - Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften - Google Patents

Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften

Info

Publication number
DE69803750T2
DE69803750T2 DE69803750T DE69803750T DE69803750T2 DE 69803750 T2 DE69803750 T2 DE 69803750T2 DE 69803750 T DE69803750 T DE 69803750T DE 69803750 T DE69803750 T DE 69803750T DE 69803750 T2 DE69803750 T2 DE 69803750T2
Authority
DE
Germany
Prior art keywords
pharmaceutically acceptable
antidiabetic
hypolipidemic
thiazolidinedione
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69803750T
Other languages
English (en)
Other versions
DE69803750D1 (de
Inventor
Bhushan Lohray
Madhavan Gurram
Rajagopalan Ramanujam
Ranjan Chakrabarti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
REDDY S RES FOUNDATION ANDHRA
Dr Reddys Research Foundation
Reddy Cheminor Inc
Original Assignee
REDDY S RES FOUNDATION ANDHRA
Dr Reddys Research Foundation
Reddy Cheminor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/982,962 external-priority patent/US6011036A/en
Application filed by REDDY S RES FOUNDATION ANDHRA, Dr Reddys Research Foundation, Reddy Cheminor Inc filed Critical REDDY S RES FOUNDATION ANDHRA
Publication of DE69803750D1 publication Critical patent/DE69803750D1/de
Application granted granted Critical
Publication of DE69803750T2 publication Critical patent/DE69803750T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69803750T 1997-12-02 1998-04-10 Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften Expired - Fee Related DE69803750T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/982,962 US6011036A (en) 1997-04-15 1997-12-02 Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
PCT/US1998/007285 WO1998045292A1 (en) 1997-12-02 1998-04-10 Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties

Publications (2)

Publication Number Publication Date
DE69803750D1 DE69803750D1 (de) 2002-03-21
DE69803750T2 true DE69803750T2 (de) 2002-09-12

Family

ID=25529696

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69803750T Expired - Fee Related DE69803750T2 (de) 1997-12-02 1998-04-10 Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften

Country Status (6)

Country Link
EP (1) EP0971917B1 (de)
JP (1) JP4391597B2 (de)
AT (1) ATE212991T1 (de)
AU (1) AU6966498A (de)
DE (1) DE69803750T2 (de)
WO (1) WO1998045292A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
EP1263458B1 (de) 2000-03-08 2005-11-16 Novo Nordisk A/S Senkung des serum cholesterols
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
WO2003055482A1 (en) 2001-12-21 2003-07-10 Novo Nordisk A/S Amide derivatives as gk activators
ATE491703T1 (de) * 2002-04-30 2011-01-15 Kudos Pharm Ltd Phthalazinonderivate
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
MXPA06003474A (es) 2003-09-30 2006-06-05 Novo Nordisk As Agonistas de receptores de melanocortina.
EP1694356B1 (de) 2003-12-09 2011-02-16 Novo Nordisk A/S Regulierung der nahrungspräferenz mit glp-1-agonisten
MXPA06007667A (es) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
WO2005105785A2 (en) 2004-05-04 2005-11-10 Novo Nordisk A/S Indole derivatives for treatment of obesity
EP1758575A1 (de) 2004-06-11 2007-03-07 Novo Nordisk A/S Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
JP2008521864A (ja) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
RU2499795C2 (ru) 2005-07-04 2013-11-27 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
EP1904467B1 (de) 2005-07-14 2013-05-01 Novo Nordisk A/S Harnstoff-Glucokinase-Aktivatoren
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
AU2006342449B2 (en) 2005-11-17 2012-03-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
KR101280333B1 (ko) 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
CA2669884A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
US8318778B2 (en) 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
CA2792663A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
CN103596583B (zh) 2011-03-28 2016-07-27 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
IN2014CN02448A (de) 2011-09-23 2015-06-19 Novo Nordisk As
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
EP3596107A1 (de) 2017-03-15 2020-01-22 Novo Nordisk A/S Bicyclische verbindungen mit fähigkeit zur bindung an den melanocortin-4-rezeptor
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
WO1998045292A1 (en) 1998-10-15
DE69803750D1 (de) 2002-03-21
ATE212991T1 (de) 2002-02-15
EP0971917B1 (de) 2002-02-06
JP4391597B2 (ja) 2009-12-24
AU6966498A (en) 1998-10-30
EP0971917A1 (de) 2000-01-19
JP2002508745A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
IL142649A0 (en) Azole derivatives
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DK0418845T3 (da) Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme
AU1120599A (en) New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
AP2001002066A0 (en) Substituted oxazoles and thiazoles derivatives at hPPAR gamma and hPPAR alpha activators
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
PT863136E (pt) Derivados de azetidina e de pirrolidina
FI970317A (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
ES2142852T3 (es) Derivados de tiazolidindiona, su produccion y uso.
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
CA2321188A1 (en) Derivatives of azetidine and pyrrolidine
KR970707122A (ko) 퀴놀린 유도체(quinoline derivative)
DE69824756D1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
MX9701116A (es) Profarmacos de 5-(2-[4-(1,2-benzoisotiazol-3-il)-1-piperazinil]etil)-6-clor o-1,3-dihidro-2h-indol-2-ona.
RS50109B (sr) Derivati 4-heterociklilsulfonamidil-6-metoksi-5-(2-metoksi- fenoksi)-2-piridil-piridimina, njihovo dobivanje i primena kao antagonisti endotelinskih receptora
DE69827614D1 (de) Chinoxalindionen
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto
RS50412B (sr) Derivati tiazofurina
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee